biostudies-literatureFan FBeijing Municipal Natural Science FoundationNIMH NIH HHSNational Natural Science Foundation of ChinaBeijing Hospitals Authority Youth ProgrammeCapital's Funds for Health Improvement and ResearchCultivation Program of Beijing Municipal Hospital AdministrationNational Institute of Health grantNIH HHS12-19https://www.ebi.ac.uk/biostudies/studies/S-EPMC9812867biostudies-literatureUnknown77(1)<h4>Aim</h4>Approximately a third of patients with schizophrenia fail to adequately respond to antipsychotic medications, a condition known as treatment resistance (TR). We aimed to assess cognitive and cortical thickness deficits and their relationship to TR in schizophrenia.<h4>Method</h4>We recruited patients with schizophrenia (n = 127), including patients at treatment initiation (n = 45), treatment-responsive patients (n = 40) and TR patients (n = 42), and healthy controls (n = 83). Clinical symptoms, neurocognitive function, and structural images were assessed. We performed group comparisons, and explored association of cortical thickness and cognition with TR.<h4>Results</h4>The TR patients showed significantly more severe clinical symptoms and cognitive impairment relative to the tPsychiatry and clinical neurosciencesAssociation of cortical thickness and cognition with schizophrenia treatment resistance.PMC9812867PX20180692018-4-213331671145S10 OD023696QML202020018140111581761128021RF1 MH123163R01MH112180R01 MH1121807182074Li HHuang JTian BDu XYang FKochunov PFan FHong LELi YHare STan YTan SChen SWang ZfalseAssociation of cortical thickness and cognition with schizophrenia treatment resistance.<h4>Aim</h4>Approximately a third of patients with schizophrenia fail to adequately respond to antipsychotic medications, a condition known as treatment resistance (TR). We aimed to assess cognitive and cortical thickness deficits and their relationship to TR in schizophrenia.<h4>Method</h4>We recruited patients with schizophrenia (n = 127), including patients at treatment initiation (n = 45), treatment-responsive patients (n = 40) and TR patients (n = 42), and healthy controls (n = 83). Clinical symptoms, neurocognitive function, and structural images were assessed. We performed group comparisons, and explored association of cortical thickness and cognition with TR.<h4>Results</h4>The TR patients showed significantly more severe clinical symptoms and cognitive impairment relative to the t2023-01-01T00:00:00Z2023 Jan2025-04-26T07:45:42.698Z2025-04-06T12:28:38.983ZS-EPMC98128673618478210.1111/pcn.13486